Literature DB >> 6157332

Enhancement of dengue virus infection in monocytes by flavivirus antisera.

S B Halstead, J S Porterfield, E J O'Rourke.   

Abstract

Enhanced dengue 2 virus (D2V) infection in suspension cultures of human peripheral blood mononuclear phagocytes (PBL) produced by subneutralizing concentrations of dengue antisera has been described previously. In this study, the enhancement phenomenon was found to be a general property of representative flavivirus antisera. All except one of 24 antisera, which had been raised by 1-3 injections of flaviviruses in rabbits, enhanced the growth of dengue 2 virus in human PBL. Flavivirus antisera showing the greatest level of cross-reactivity against a battery of 42 flavivirus antigens in the hemagglutination-inhibition test were most potent in enhancing dengue replication in PBL cultures. Cross-neutralizing reactivity did not relate to enhanced D2V infection. However nearly one-half of studied flavivirus antisera neutralized D2V at dilutions of 1:10 or 1:20. Heterotypic D2V neutralizing antibody could serve as a "brake" on infection enhancement in vivo. Observations should be made in the field to look for possible enhancement of dengue infection in heterotypic flavivirus immunes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6157332     DOI: 10.4269/ajtmh.1980.29.638

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  57 in total

1.  Release of vasoactive cytokines by antibody-enhanced dengue virus infection of a human mast cell/basophil line.

Authors:  C A King; J S Marshall; H Alshurafa; R Anderson
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

Review 3.  Closing the door on flaviviruses: entry as a target for antiviral drug design.

Authors:  Rushika Perera; Mansoora Khaliq; Richard J Kuhn
Journal:  Antiviral Res       Date:  2008-06-11       Impact factor: 5.970

4.  The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens.

Authors:  N Ferguson; R Anderson; S Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

5.  Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes.

Authors:  R Anderson; S Wang; C Osiowy; A C Issekutz
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

Review 6.  Assessing the global threat from Zika virus.

Authors:  Justin Lessler; Lelia H Chaisson; Lauren M Kucirka; Qifang Bi; Kyra Grantz; Henrik Salje; Andrea C Carcelen; Cassandra T Ott; Jeanne S Sheffield; Neil M Ferguson; Derek A T Cummings; C Jessica E Metcalf; Isabel Rodriguez-Barraquer
Journal:  Science       Date:  2016-07-14       Impact factor: 47.728

Review 7.  The global distribution of yellow fever and dengue.

Authors:  D J Rogers; A J Wilson; S I Hay; A J Graham
Journal:  Adv Parasitol       Date:  2006       Impact factor: 3.870

8.  A relevant in vitro human model for the study of Zika virus antibody-dependent enhancement.

Authors:  Berlin Londono-Renteria; Andrea Troupin; Jenny C Cardenas; Alex Hall; Omar G Perez; Lucio Cardenas; Adam Hartstone-Rose; Scott B Halstead; Tonya M Colpitts
Journal:  J Gen Virol       Date:  2017-07-08       Impact factor: 3.891

9.  Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.

Authors:  P J Klasse
Journal:  Adv Biol       Date:  2014-09-09

10.  Clinical findings and pro-inflammatory cytokines in dengue patients in Western India: a facility-based study.

Authors:  D Priyadarshini; Rajesh R Gadia; Anuradha Tripathy; K R Gurukumar; Asha Bhagat; Sampada Patwardhan; Nitin Mokashi; Dhananjay Vaidya; Paresh S Shah; D Cecilia
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.